Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 12/20 | 0.44 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.44 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7340855 | 0.87 | TSHR (0.45) | GPR132CMKLR2CMKLR1TP53ALDH1A1 | |
| SCHEMBL6773680 | 0.86 | ALDH1A1 (0.44) | GPR132CMKLR2CMKLR1ALDH1A1LMNA | |
| SCHEMBL6773448 | 0.85 | KMT2A (0.55) | ALDH1A1LMNA | |
| SCHEMBL7835677 | 0.85 | GPR132 (0.42) | GPR132CMKLR2CMKLR1TP53ALDH1A1 | |
| SCHEMBL7835626 | 0.85 | TSHR (0.48) | GPR132CMKLR2CMKLR1TP53ALDH1A1 | |
| SCHEMBL6779491 | 0.83 | TSHR (0.55) | LMNA | |
| SCHEMBL7338811 | 0.82 | GPR132 (0.46) | GPR132CMKLR2CMKLR1TP53ALDH1A1 | |
| SCHEMBL7345153 | 0.82 | TSHR (0.46) | GPR132CMKLR2CMKLR1TP53 | |
| SCHEMBL7836894 | 0.82 | NAMPT (0.59) | LMNA | |
| SCHEMBL7836417 | 0.81 | GPR139 (0.49) | GPR132CMKLR2CMKLR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |